Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Anika Therapeutics Inc (NASDAQ:ANIK)

37.01
Delayed Data
As of 12:03pm ET
 -0.62 / -1.65%
Today’s Change
30.93
Today|||52-Week Range
45.35
-3.01%
Year-to-Date
Immunomedics (IMMU) in Focus: Stock Moves 20.9% Higher
8:47am / Zacks.com
Prothena (PRTA) Looks Good: Stock Jumps 5.1% in Session
Feb 01 / Zacks.com
Amgen's Blincyto and Repatha Positive in Phase III Studies
Feb 05 / Zacks.com
AstraZeneca's Lynparza Gets Breakthrough Therapy Status
Jan 29 / Zacks.com
Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Feb 05 / Zacks.com
Merck's HCV Drug Zepatier Gets FDA Nod; Sets Lower Price
Jan 29 / Zacks.com
AstraZeneca Tops Q4 Earnings, Falls on Bleak 2016 Outlook
Feb 05 / Zacks.com
Exelixis's Cabozantinib Granted Priority Review in the U.S.
Jan 29 / Zacks.com
Glaxo Tops Q4 Earnings, Revenues Rise Y/Y, 2016 View Intact
Feb 04 / Zacks.com
SurModics' (SRDX) Q1 Earnings & Revenues Beat Estimates
Jan 29 / Zacks.com
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.3%
Feb 04 / Zacks.com
Inovio Pharmaceuticals (INO) Jumps: Stock Moves Up 7.6%
Jan 29 / Zacks.com
Sanofi Begins Search for Vaccine for Zika Virus as Fear Grows
Feb 03 / Zacks.com
Clovis (CLVS) Begins Immunotherapy Combination Study
Jan 28 / Zacks.com
Myriad Genetics Tops Q2 Earnings; myRisk Conversion Over
Feb 03 / Zacks.com
MannKind (MNKD) Shows Strength: Stock Moves 14% Higher
Jan 28 / Zacks.com
Qiagen Q4 Earnings Miss, Molecular Diagnostics Disappoints
Feb 03 / Zacks.com
Alkermes Initiates Early-Stage Study on Alzheimer's Drug
Jan 27 / Zacks.com
Bio-Techne (TECH) Q2 Earnings Match, Sales Beat Estimates
Feb 03 / Zacks.com
Affimed & Merck Ink Deal for AFM13-Keytruda Combination
Jan 27 / Zacks.com
Alexion Misses on Earnings and Revenues in Q4, Gives View
Feb 03 / Zacks.com
Amgen's Biosimilar of AbbVie's Humira under FDA Review
Jan 27 / Zacks.com
Gilead (GILD) Beats Q4 Earnings Estimates, Gives 2016 View
Feb 03 / Zacks.com
OncoMed Tanks on Phase II Pancreatic Cancer Study Update
Jan 27 / Zacks.com
Jazz's Phase III Data on Defibrotide Published in ASH Journal
Feb 02 / Zacks.com
Fate (FATE) to Move ProTmune into Phase I/II Study in Mid-16
Jan 27 / Zacks.com
ARIAD (ARIA) to Move AP32788 into Phase I/II Study in 2Q16
Feb 02 / Zacks.com
Argos Therapeutics (ARGS) Catches Eye: Stock Rises 35.9%
Jan 27 / Zacks.com
Argos Therapeutics (ARGS) Jumps: Stock Moves Up 19.6%
Feb 02 / Zacks.com
Amgen Presents Encouraging Phase III Data on Vectibix
Jan 25 / Zacks.com
Spectrum (SPPI) Initiates Phase III Study on SPI-2012
Feb 01 / Zacks.com